SustainabilityESG Data

Environmental

INPUT

Items Units FY2019 FY2020 FY2021 FY2022 FY2023
Energy consumption
Electricity Thousand kwh 92,077 88,772 90,196 115,948 126,457
(of which) In-house power generation Thousand kwh 3,175 2,278 2,239 1,465 852
(of which) Solar power (On-Site Power Purchase Agreement) Thousand kwh - - 96 285 269
(of which) CO2-free electricity (Derived from non-fossil power sources) Thousand kwh - - - - 8,033
Kerosene kl 1,893 1,970 1,991 1,728 2,088
Heavy oil (A type) kl 942 761 736 511 308
Light oil kl 0 0 0.09 0 0.17
LPG t 5 4 1 2,187 1,274
City gas Thousand m3 3,981 3,817 3,984 4,971 4,752
Non-industrial steam GJ 64,870 65,146 56,700 55,484 56,237
Crude oil equivalent kl 31,015 30,130 30,452 40,628 36,955
Water
Amount of water used (Clean water, industrial water and desalinated water used) Thousand m3 405 367 360 357 348
Per unitAmount of water used divided by production volume (unit: hundred million tablets) - 1.7 1.6 1.4 1.2 1.3
(of which) clean water Thousand m3 368 330 325 307 307
(of which) industrial water Thousand m3 36 37 35 50 41

* Sawai Pharmaceutical only (before FY2020)
* Including even Kaken Shouyaku's data except water (from FY2021 onward)
* Including even Trust Pharmatech's data except water (from FY2022 onward)

OUTPUT

Items Units FY2019 FY2020 FY2021 FY2022 FY2023
Water
Total drainage volume Thousand m3 390 360 353 330 324
(of which) sewer drainage Thousand m3 143 152 165 142 131
(of which) river drainage Thousand m3 50 48 39 37 38
(of which) Others Thousand m3 197 160 149 151 154
CO2
CO2 emission kt-CO2 53.1 50.5 53.3 67.9 73.2
(of which) CO2-free electricity (Derived from non-fossil power sources) kt-CO2 - - - - 3.4
CO2 emission (After offset) kt-CO2 53.1 50.5 53.3 67.9 69.8
Per unitEmission volume (After offset) divided by production volume (unit: billion tablets) - 2.2 2.1 2.0 2.4 2.5
(of which) Scope1 CO2 emission kt-CO2 15.5 14.8 15.2 22.7 19.5
(of which) Scope2 CO2 emission (After offset) kt-CO2 37.6 35.6 38.1 46.5 50.3
Scope3 CO2 emission
Total Scope3 emissions in the value chains kt-CO2 196.4 194.6 222.5 256.6 231.2
1. Purchased goods and services kt-CO2 165.2 156.8 188.9 198.7 198.4
2. Capital goods kt-CO2 10.4 17.6 12.2 36.0 10.8
3. Fuel-and energy-related activities (not included in scope 1 or scope 2) kt-CO2 8.2 8.0 7.8 8.1 8.3
4. Upstream transportation and distribution kt-CO2 N/A N/A N/A N/A N/A
5. Waste generated in operations kt-CO2 0.9 0.9 1.0 1.1 1.1
6. Business travel kt-CO2 0.4 0.2 0.2 0.2 0.2
7. Employee commuting kt-CO2 1.0 0.9 0.9 1.1 1.1
8. Upstream leased assets kt-CO2 N/A N/A N/A N/A N/A
9. Downstream transportation and distribution kt-CO2 9.9 9.8 10.7 10.3 10.3
10. Processing of sold products kt-CO2 N/A N/A N/A N/A N/A
11. Use of sold products kt-CO2 N/A N/A N/A N/A N/A
12. End-of-life treatment of sold products kt-CO2 N/A N/A N/A N/A N/A
13. Downstream leased assets kt-CO2 N/A N/A N/A N/A N/A
14. Franchises kt-CO2 N/A N/A N/A N/A N/A
15. Investments kt-CO2 0.5 0.5 0.8 1.1 1.1
Waste
Amount of waste, etc. t 2,095 1,981 2,094 2,285 2,449
Per unitDischarge amount divided by production volume (unit: hundred million tablets) - 8.9 8.4 7.9 7.9 8.8
Recycled volume t 1,132 946 1,363 1,508 1,430
Recycling rate % 54 48 65 66 58
Chemical substances, etc.
Amount of release and transfer of specified chemical substances
Subjects: acetonitrile and methylene chloride (dichloromethane) (before FY2022)
methylene chloride (dichloromethane), xylene, trimethylbenzene, methylnaphthalene (from FY2023 onward) 		t 29 27 31 32 13
NOx t 21 18 20 5 4
SOx t 2 1 1 1 0.3

* Sawai Pharmaceutical only (before FY2020)
* Including even Kaken Shouyaku's data except water and Scope3 CO2 emission (from FY2021 onward)
* Including even Trust Pharmatech's data except water and Scope3 CO2 emission (from FY2022 onward)

Social

Status of Employees

Items Units FY2019 FY2020 FY2021 FY2022 FY2023
Number of Employees Persons 3,066 3,003 2,968 3,393 3,482
Japan Persons 2,491 2,444 2,474 2,944 3,037
US Persons 575 559 494 449 445
Average number of temporary employees Persons 366 327 330 346 341
Japan Persons 333 298 310 328 333
US Persons 33 29 20 18 8
Number of Employees*1 Persons 2,491 2,444 2,474 2,944 3,037
Manufacturing Persons 1,644 1,607 1,636 2,015 2,097
R&D Persons 251 246 253 295 297
Administration, Sales Persons 596 591 585 634 643
Male Persons 1,672 1,642 1,663 1,920 1,961
Female Persons 819 802 811 1,024 1,076
Male (Ratio) % 67.1 67.2 67.2 65.2 64.6
Female (Ratio) % 32.9 32.8 32.8 34.8 35.4
Number of employees in managerial positions*1 Persons 247 258 256 262 288
Number of MRs*2 Persons 394 382 379 375 376
Number of persons with pharmacist qualifications*3 Persons 261 256 255 246 260
Mean age*4 Age 38.0 38.6 38.8 38.2 38.1
Male Age 37.9 38.7 38.6 38.2 38.3
Female Age 38.1 38.6 39.0 38.0 38.0
Average length of service*4 Years 8.2 8.9 9.3 8.9 9.3
Male Years 8.3 9.1 9.5 9.2 9.7
Female Years 7.8 8.5 8.8 8.3 8.5
Number of recruits*4 Persons 69 76 166 201 227
Hiring of new graduates Persons 11 10 49 83 102
(of which) Male Persons 3 5 33 44 59
(of which) Female Persons 8 5 16 39 43
New employees transferred from other company, etc. Persons 58 66 117 118 125
(of which) Male Persons 30 28 79 82 90
(of which) Female Persons 28 38 38 36 34
Employee turnover*4 % 5.7 2.8 3.3 3.1 4.1
Retention of new graduates (at the time after 3years of employment)*4 % 94.6 94.7 92.9 93.7 92.5
Salary and benefit*5 Million yen 5,161 5,132 661 722 686
Ratio of employees covered by the collective agreements*1 % 90.1 89.4 89.7 91.1 90.5
Unionization rate (Sawai Pharmaceutical Workers Union)*1 % 75.9 77.1 80.5 85.1 86.1

*1 Sawai Pharmaceutical, Medisa Shinyaku and Kaken Shoyaku, Trust Pharmatec (from FY2022 onward)
*2 Sawai Pharmaceutical and Kaken Shoyaku
*3 Sawai Pharmaceutical, Trust Pharmatec (from FY2022 onward)
*4 Sawai Pharmaceutical
*5 Sawai Pharmaceutical (before FY2020), Sawai Group Holdings (from FY2021 onward)

Diversity Promotion*1

Items Units FY2019 FY2020 FY2021 FY2022 FY2023
Number of foreign national employees Persons 7 6 7 7 8
Number of female employees in managerial positions Persons 15 15 17 18 22
Ratio of female employees in managerial positions*2 % 6.1 5.8 6.6 6.9 8.3
Ratio of disabled employees*3 % 1.78 2.48 2.38 2.57 2.54
Number of employees rehired after retirement Persons 43 43 59 78 103
Percentage of rehired employees who retired at retirement age % 88.2 95.2 87.5 96.4 81.8
Percentage of mid-career employees in managerial positions % 60 56 61 63 60

*1 Sawai Pharmaceutical only
*2 Sawai Pharmaceutical (before FY2022), Sawai Group (from FY2023 onward). Target ratio of female employees in managerial positions: 15% and above by the end of March 2027.
*3 Target: To maintain the level over the statutory employment ratio of disabled employees. The statutory employment ratio for disabled employees since April 2025 is 2.7%. The figures are as of June 1 of the following year.

Work Environment*1

Items Units FY2019 FY2020 FY2021 FY2022 FY2023
Paid leave utilization rate*2 % 75.0 72.9 71.1 80.5 82.2
Number of employees who take child-care leave Persons 74 74 42 49 72
(of which) Male Persons - - 10 20 38
(of which) Female Persons - - 32 29 34
Child-care leave utilization rate*3 % 2.7 2.7 34.7 50.0 55.0
Return rate from child-care leave % 96.9 91.7 100 100 100
Number of employees who take family-care leave Persons 4 3 0 1 3
Average hours of overtime work per month*4 Hours - 16.5 17.7 15.8 15.8
Stress check examination rate % - - 97.6 97.8 98.1
Medical checkup rate % - - 100 100 100
Smokers rate % 14.2 13.7 12.8 12.7 11.9
Frequency rate of occupational injuries % 0.87 0 0 0.54 0.89

*1 Sawai Pharmaceutical only
*2 Eligible Persons: Union members, Terms: From 1st Jan. to 31st Dec.
*3 (FY2020 and before) Denominator is the number of employees as of the end of March. (FY2021 and after) Denominator is the number of employees who gave birth to children by themselves or their spouses among Sawai-registered or transferred employees to Sawai.
*4 Including employees transferred from Sawai Pharmaceutical to Sawai Group companies.

Employee Growth

Items Units FY2019 FY2020 FY2021 FY2022 FY2023
Number of employee-training*1 Times 16 - - - -
Number of employees trained*2 Persons 600 4,038 2,840 4,034 3,795
Employee training expenses*3 Million yen 62 45 63 88 92
Pass rate of MR certification test*3 % is not applicable is not applicable is not applicable 100 100

*1 Sawai Pharmaceutical. Not counted since FY2020 due to diversification of training methods and contents.
*2 Sawai Pharmaceutical. From FY2020 the number of participants in e-learning, etc. is included.
*3 Sawai Pharmaceutical, Medisa Shinyaku and Kaken Shoyaku

Products / Stable Supply

Items Units FY2019 FY2020 FY2021 FY2022 FY2023
Number of products*1 Items 740 780 790 790 770
Number of new products launched*2 - 5 generic drugs with 12 strengths 19 generic drugs with 44 strengths 13 generic drugs with 32 strengths 11 generic drugs with 23 strengths 3 generic drugs with 10 strengths
No. of tablets sold*2 Billion tablets 12.4 13.3 14.8 15.0 157
Number of patents owned*2 Items 36 37 42 45 53
Number of patents pending*2 Cases 31 38 44 32 30
Number of raw material supplier audits*3 Times 188 120 168 212 153
Number of inquiries to drug information center*2 Cases 46,800 48,600 49,800 46,700 46,468
Number of out of stock products*2 Items 4 8 16 6 16
Product recall (Class Ⅰ)*3 Cases 1 0 0 0 0
Product recall (Class Ⅱ)*3 Cases 1 7 8 5 11
Product recall (Class Ⅲ)*3 Cases 0 0 0 0 0

*1 Sawai Pharmaceutical (The figures are as of April 1 of the following year)
*2 Sawai Pharmaceutical
*3 Sawai Pharmaceutical (before FY2020), Sawai Group in Japan (from FY2021 onward)

Promotion of Communication

Items Units FY2019 FY2020 FY2021 FY2022 FY2023
Dialogue with institutional investors and analysts*1 Times 124 129 141 154 191
Communication with Mass Media*2 Times 38 28 42 59 38
Factory tours Times 164 16 12 45 113
Expenditures for social contribution activities Million yen 76 51 212 220 259

*1 Total
*2 Interview, brief session, etc.

Medical cost-saving impact

Items Units FY2019 FY2020 FY2021 FY2022 FY2023
Medical cost-saving impact (Japan) Billion yen 296.7 317.6 338.2 280.9 293.9

Governance

Items Units FY2019 FY2020 FY2021 FY2022 FY2023
Number of directors (board members) Persons 7 6 6 6 5
Number of external directors Persons 2 2 2 2 3
Ratio of external directors % 28.6 33.3 33.3 33.3 60.0
Number of female directors Persons 1 1 1 1 1
Ratio of female directors % 14.3 16.7 16.7 16.7 20.0
Number of Audit & Supervisory Board members Persons 4 3 3 3 3
Number of external Audit & Supervisory Board members Persons 2 2 2 2 2
Ratio of external Audit & Supervisory Board members % 50.0 66.7 66.7 66.7 66.7
Number of corporate officers Persons 10 12 8 11 8
(of which) Number of female corporate officers Persons 1 1 0 1 1
Number of board meetings Times 16 16 13 13 14
Number of attendances of external directors
Masatoshi Ohara Attendance/Total
%		 12/13
92.3%		 16/16
100%		 13/13
100%		 13/13
100%		 13/14
92.9%
Nawomi Todo Attendance/Total
%		 16/16
100%		 16/16
100%		 13/13
100%		 13/13
100%		 14/14
100%
Masayuki Mitsuka Attendance/Total
%		 - - - - 11/11
100%
Number of attendances of external Audit & Supervisory Board members
Takanobu Tomohiro Attendance/Total
%		 15/16
93.8%		 14/16
87.5%		 13/13
100%		 13/13
100%		 14/14
100%
Junichi Hirano Attendance/Total
%		 16/16
100%		 15/16
93.8%		 13/13
100%		 13/13
100%		 14/14
100%
Number of Audit & Supervisory Board meetings Times 19 18 16 13 13
Number of attendances of external Audit & Supervisory Board members
Takanobu Tomohiro Attendance/Total
%		 18/19
94.7%		 16/18
88.9%		 16/16
100%		 13/13
100%		 13/13
100%
Junichi Hirano Attendance/Total
%		 19/19
100%		 17/18
94.4%		 16/16
100%		 13/13
100%		 13/13
100%
Number of matters to be resolved at the board meeting Cases 100 106 77 71 82
Number of matters to be reported at the board meeting Cases 150 92 62 53 74
Total compensation allocation for directors (board members) and Audit & Supervisory Board members
Number of eligible directors (excluding external directors) Persons 6 5 4 4 5
Total compensation allocation Million yen 399 299 177 292 118
(of which) Fixed compensation Million yen 244 205 177 153 77
(of which) Stock options Million yen 40 24 - 84 15
(of which) Performance-based compensation Million yen 81 70 - 55 26
(of which) Retirement benefits Million yen 34 - - - -
Number of eligible Audit & Supervisory Board members (excluding external Audit & Supervisory Board members) Persons 2 2 1 1 1
Total compensation Million yen 22 18 17 17 18
(of which) Fixed compensation Million yen 22 18 17 17 18
Number of eligible exernal directors and external Audit & Supervisory Board members Persons 5 4 4 4 5
Total compensation, etc. Million yen 24 25 28 30 42
(of which) Fixed compensation Million yen 24 25 28 30 42
Number of days between the dates of dispatch of the convocation notice and annual shareholder’s meeting Days 18 18 (Jun.)
17 (Dec.)		 Meeting not held due to the
transformation
into a holding company		 17 18
Number of cases of whistle-blowing (including consultation) or whistle blowers (Japan) Cases 14 8 7 6 7
Exclusion recommended by the Fair Trade Commission, etc. (Japan) Cases 0 0 0 0 0
Shut down or suspension of business caused by scandal or misconduct (Japan) Cases 0 0 0 0 0
Criminal indictments for accidents or incidents related to compliance violations (Japan) Cases 0 0 0 0 0
Detection by price cartel (Outside Japan) Cases 0 0 0 0 0
Detection by bribery (Outside Japan) Cases 0 0 0 0 0
Detection by other reasons (Outside Japan) Cases 0 0 0 0 0

* Data on Board and Audit & Supervisory Board is for Sawai Pharmaceutical (before FY2020), for Sawai Group Holdings (from FY2021 onward)

Back to Sustainability Top